Searched for
CLARIS OTSUKA.
Carlyle in talks to invest $100 million in BDR PharmaBDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA.- High costs of Baxter deal draw Claris investors' ireThe stock, which has gained 13% so far this year, fell 7.5% to Rs 335.70 on Thursday.
- Baxter to acquire Claris Injectables for Rs 4,237 crore"The Boards of Directors of both companies have approved the proposed acquisition, which is expected to close in the second half of 2017," ...
- Top PE firms join race for Claris Lifesciences’ US businessThe business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma co...
- Baxter emerges as frontrunner to buy KKR-backed Gland Pharma for $1.1-1.2 billionHyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...
- Cadila Healthcare to acquire Claris Lifesciences for Rs 3,400 croreBoth sides are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said at least five so...
- Limited options in food and lifestyle for Japanese investors and employess in GujaratAhmedabad has just one restaurant serving Japanese food, Café Formula by Tamura, a joint initiative between Japanese restaurant chain Tamur...
- Big pharma eyes takeover of Claris’ injectables business for Rs 2500-Rs 3000 croreCarlyle private equity backed CLL has transferred its speciality injectables business into a wholly owned subsidiary called CIL.
- Claris Lifesciences completes transfer of Speciality Injectable BusinessShareholders of the company approved the transfer along with all employees, assets and liabilities at a consideration not less than its boo...
- Claris to buy-back 14.49 per cent stake for Rs 231.25 crore"The objective of the buy-back is to return surplus cash to the equity shareholders of the company," Claris said in a filing to the BSE.
- Deal with Ranbaxy: Should Daiichi Sankyo have followed the Nemawashi way?A core value of Japanese business is trust. And this is where Daiichi Sankyo’s Ranbaxy problem may start to hurt India-Japan ties.
- Claris transfers two businesses to Japan JV for Rs 1,050 crClaris will continue to hold a 20 per cent stake in the JV, while Otsuka and Mitsui will hold 60 and 20 per cent in it, respectively, a com...
- Claris Lifesciences gets FIPB nod for Japanese JV, Q1 net down by 29%Ahmedabad-based Claris Lifesciences registered de-growth of 29% in its first quarter ended on 31st March 2013.
- Govt approves 12 FDI proposals worth over Rs 2,609 crThe government today said it has approved 12 FDI proposals, including that of pharma firm Claris Otsuka, totalling over Rs 2,609 crore.
- Ten stocks in focus in Monday morning tradeIndian shares are expected to trade in a range. Here is a list of ten stocks that are likely to be in action in morning trade today.
- FDC owners in talks to exit; plan to sell their 67% stakeBuyout fund Carlyle had shown interest in buying the company and had even valued it at about Rs 3,800 crore.
- Claris Lifesciences to invest Rs 900 crore on business growth, pre-payment of debtClaris Lifesciences on Thursday said it will invest Rs 900 crore, which it expects to receive as part of divestment of 80 per cent stake in...
- Claris Lifesciences inks JV with Japanese drug maker Otsuka Pharma & Mitsui for Indian marketAhmedabad-based Claris Lifesciences Limited, India executed agreements for a Joint Venture with two Japan-based drug makers Otsuka Pharmace...
- Claris Lifesciences in talks with Otsuka Pharma to sell injectables business: SourcesShares of Claris have rallied 165 per cent from the start of the year and are currently trading at their lifetime high.
Load More
